LT3532459T - Lsd1 inhibitoriai ir jų medicininis panaudojimas - Google Patents

Lsd1 inhibitoriai ir jų medicininis panaudojimas

Info

Publication number
LT3532459T
LT3532459T LTEPPCT/US2017/058405T LTUS2017058405T LT3532459T LT 3532459 T LT3532459 T LT 3532459T LT US2017058405 T LTUS2017058405 T LT US2017058405T LT 3532459 T LT3532459 T LT 3532459T
Authority
LT
Lithuania
Prior art keywords
medical uses
lsd1 inhibitors
lsd1
inhibitors
medical
Prior art date
Application number
LTEPPCT/US2017/058405T
Other languages
English (en)
Inventor
Francois BRUCELLE
Victor GEHLING
Avinash KHANNA
Original Assignee
Constellation Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Constellation Pharmaceuticals, Inc. filed Critical Constellation Pharmaceuticals, Inc.
Publication of LT3532459T publication Critical patent/LT3532459T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/12—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LTEPPCT/US2017/058405T 2016-10-26 2017-10-26 Lsd1 inhibitoriai ir jų medicininis panaudojimas LT3532459T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662413166P 2016-10-26 2016-10-26
US201662413162P 2016-10-26 2016-10-26
PCT/US2017/058405 WO2018081343A1 (en) 2016-10-26 2017-10-26 Lsd1 inhibitors and medical uses thereof

Publications (1)

Publication Number Publication Date
LT3532459T true LT3532459T (lt) 2023-11-10

Family

ID=60320993

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2017/058405T LT3532459T (lt) 2016-10-26 2017-10-26 Lsd1 inhibitoriai ir jų medicininis panaudojimas

Country Status (17)

Country Link
US (3) US10517849B2 (lt)
EP (1) EP3532459B1 (lt)
JP (1) JP7142633B2 (lt)
CN (1) CN109863137B (lt)
AU (1) AU2017348100B2 (lt)
CA (1) CA3039793A1 (lt)
DK (1) DK3532459T3 (lt)
ES (1) ES2961499T3 (lt)
FI (1) FI3532459T3 (lt)
HR (1) HRP20231369T1 (lt)
HU (1) HUE063848T2 (lt)
LT (1) LT3532459T (lt)
PT (1) PT3532459T (lt)
RS (1) RS64889B1 (lt)
SI (1) SI3532459T1 (lt)
TW (1) TWI753037B (lt)
WO (1) WO2018081343A1 (lt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20231369T1 (hr) 2016-10-26 2024-02-16 Constellation Pharmaceuticals, Inc. Inhibitori lsd1 i njihova medicinska upotreba
KR20200036920A (ko) 2017-08-03 2020-04-07 오리존 지노믹스 에스.에이. 행동 변경 치료 방법
EP3851440A4 (en) * 2018-09-13 2022-06-08 Helioeast Pharmaceutical Co., Ltd. CYCLOPROPYLAMINE COMPOUND AS AN LSD1 INHIBITOR AND USE OF IT
MX2021011254A (es) 2019-03-20 2021-10-01 Oryzon Genomics Sa Metodos de tratamiento del trastorno por deficit de atencion e hiperactividad.
CA3130638A1 (en) 2019-03-20 2020-09-24 Oryzon Genomics, S.A. Methods of treating borderline personality disorder
CN114341366A (zh) 2019-07-05 2022-04-12 奥莱松基因组股份有限公司 用于使用kdm1a抑制剂个体化治疗小细胞肺癌的生物标志物和方法
TW202304416A (zh) 2021-04-08 2023-02-01 西班牙商奧萊松基因組股份有限公司 用於治療骨髓癌的ｌｓｄ１抑制劑的組合
WO2023217784A1 (en) 2022-05-09 2023-11-16 Oryzon Genomics, S.A. Methods of treating nf1-mutant tumors using lsd1 inhibitors
WO2023217758A1 (en) 2022-05-09 2023-11-16 Oryzon Genomics, S.A. Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors
WO2024110649A1 (en) 2022-11-24 2024-05-30 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors and menin inhibitors for treating cancer

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4639273A (en) 1983-05-06 1987-01-27 Morton Thiokol, Inc. Asphalt-adhesion improving additives prepared by formaldehyde condensation with polyamines
JP2656522B2 (ja) 1986-06-13 1997-09-24 ザ ルブリゾル コーポレーション リン含有の潤滑剤および機能流体組成物
US5188927A (en) 1990-06-15 1993-02-23 Fuji Photo Film Co., Ltd. Composition and process for the processing of silver halide color photographic material
WO1992017456A1 (en) 1991-03-26 1992-10-15 Fujisawa Pharmaceutical Co., Ltd. Amino acid derivative and salt thereof
TW230781B (lt) 1991-05-13 1994-09-21 Lubysu Co
US5344467A (en) 1991-05-13 1994-09-06 The Lubrizol Corporation Organometallic complex-antioxidant combinations, and concentrates and diesel fuels containing same
FR2687932A1 (fr) 1992-02-27 1993-09-03 Oreal Dispersion huile-dans-l'eau susceptible de former des films composites.
DE4224414A1 (de) 1992-07-24 1994-01-27 Cassella Ag Phenylimidazolidin-derivate, ihre Herstellung und ihre Verwendung
DE4228717A1 (de) 1992-08-28 1994-03-03 Cassella Ag Imidazolidin-Derivate
EP0678786B1 (en) 1994-04-19 1998-06-17 Agfa-Gevaert N.V. A method for making a lithographic printing plate
DE19523288A1 (de) 1995-06-27 1997-01-02 Basf Ag Iminooxybenzylverbindungen, Verfahren zu ihrer Herstellung und ihre Verwendung
SE9600590D0 (sv) 1996-02-19 1996-02-19 Pharmacia Biotech Ab Sätt för kromatografisk separation av peptider och nukleinsyra samt ny högaffin jonbytesmatris
US6492380B1 (en) 1999-05-17 2002-12-10 Queen's University At Kingston Method of inhibiting neurotrophin-receptor binding
CA2374239A1 (en) 1999-06-15 2000-12-21 Albert J. Robichaud Substituted heterocycle fused gamma-carbolines
ECSP003599A (es) 1999-08-06 2002-03-25 Smithkline Beecham Corp Procedimiento para preparar acidos a traves de alfa-coroepoxi-esteres
MY158895A (en) 2000-05-19 2016-11-30 Monsanto Technology Llc Potassium glyphosate formulations
US7135437B2 (en) 2000-05-19 2006-11-14 Monsanto Technology Llc Stable liquid pesticide compositions
US6828329B2 (en) 2000-06-26 2004-12-07 Neurogen Corporation Aryl fused substituted 4-oxy-pyridines
US7008904B2 (en) 2000-09-13 2006-03-07 Monsanto Technology, Llc Herbicidal compositions containing glyphosate and bipyridilium
US6518444B1 (en) 2000-12-18 2003-02-11 Univation Technologies, Llc Preparation of polymerization catalysts
US20030096708A1 (en) 2001-03-02 2003-05-22 Monsanto Technology Llc Pesticide concentrates containing etheramine surfactants
RU2297143C2 (ru) 2001-05-21 2007-04-20 Монсанто Текнолоджи Ллс Водная гербицидная композиция (варианты) и гербицидный способ (варианты)
WO2003003008A1 (en) 2001-06-29 2003-01-09 7Tm Pharma A/S Chemical libraries useful for drug discovery processes
JP2003064035A (ja) 2001-08-28 2003-03-05 Sony Corp 部分フッ化アルキル系化合物、該化合物からなる潤滑剤および該潤滑剤を用いた記録媒体
KR100577179B1 (ko) 2001-10-30 2006-05-10 엘지전자 주식회사 유기 전계 발광 소자
DE10302781B4 (de) 2002-02-23 2015-08-27 Merck Patent Gmbh Verfahren zur α,α-Difluoralkylierung von Stickstoffnucleophilen
WO2004014377A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc 4-hydroxyquinoline derivatives as matrix metalloproteinase inhibitors
WO2004014388A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc 6,6-fused heteroaryl derivatives as matrix metalloproteinase inhibitors
FR2843750B1 (fr) 2002-08-23 2004-10-22 Cerep Composes derives d'arylcarbamates, preparation et utilisations
CA2496570C (en) 2002-08-31 2012-07-10 Monsanto Technology Llc Pesticide compositions containing dicarboxylic acids
JP4666256B2 (ja) 2002-12-10 2011-04-06 小野薬品工業株式会社 含窒素複素環化合物およびその医薬用途
JP4123361B2 (ja) 2002-12-11 2008-07-23 ライオン株式会社 漂白性組成物
DE602004011193D1 (de) 2003-03-07 2008-02-21 Kawaken Fine Chemicals Co Verfahren zur herstellung von optisch aktivem alkohol in gegenwart von rhodium, einem chiralen ferrocenyldiphosphin und einem optisch aktivem diamin
US7678281B2 (en) 2003-07-18 2010-03-16 Bj Services Company Method of reclaiming brine solutions using an organic chelant
US7172703B2 (en) 2003-07-18 2007-02-06 Bj Services Co Method of reclaiming a well completion brine solutions using an organic chelant
US20070099938A1 (en) 2003-10-24 2007-05-03 Ono Pharmaceutical Co., Ltd. Antistress drug and medical use thereof
JP4789966B2 (ja) 2004-04-09 2011-10-12 大塚製薬株式会社 医薬組成物
CN1942433A (zh) 2004-04-27 2007-04-04 北卡罗来纳查佩尔山大学 通过液相色谱法分离不对称二亚胺
DE102005022593A1 (de) 2004-05-18 2006-02-16 Sasol Wax (South Africa) (Pty.) Ltd. Polymerisation von Olefinverbindungen
WO2005118543A1 (ja) 2004-06-03 2005-12-15 Ono Pharmaceutical Co., Ltd. キナーゼ阻害薬およびその用途
WO2005123884A2 (en) 2004-06-18 2005-12-29 Sasol Technology (Pty) Limited Oligomerisation in the presence of both a tetramerisation catalyst and a further oligomerisation catalyst
PL1773768T3 (pl) 2004-07-30 2019-03-29 Exelixis, Inc. Pochodne pirolu jako środki farmaceutyczne
FR2874010B1 (fr) 2004-08-04 2006-09-29 Rhodia Chimie Sa Procede d'acylation de composes nucleophiles notamment anilines
GB0421285D0 (en) 2004-09-24 2004-10-27 Univ Nottingham Improvements in high content screening
WO2006038594A1 (ja) 2004-10-04 2006-04-13 Ono Pharmaceutical Co., Ltd. Ｎ型カルシウムチャネル阻害薬
JP2008515821A (ja) 2004-10-06 2008-05-15 レセプトイコン・アンパルトセルスカブ 薬物誘発性細胞毒性の予防のための化合物の使用
AU2006275694A1 (en) 2005-07-28 2007-02-08 Bristol-Myers Squibb Company Substituted tetrahydro-1H-pyrido(4,3,b)indoles as serotonin receptor agonists and antagonists
US7795436B2 (en) 2005-08-24 2010-09-14 Bristol-Myers Squibb Company Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
EP1924546A1 (en) 2005-09-14 2008-05-28 Amgen, Inc Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
BRPI0617348A2 (pt) 2005-10-13 2011-07-26 Wyeth Corp mÉtodos para a preparaÇço de derivados de Ácido glutÂmico; e compostos preparados por esses mÉtodos
GB0526240D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
WO2007116011A2 (de) 2006-04-10 2007-10-18 Basf Se Substituierte triazolopyrimidine, verfahren zu ihrer herstellung und ihre verwendung zur bekämpfung von schadpilzen sowie sie enthaltende mittel
JP4771975B2 (ja) 2007-02-27 2011-09-14 三菱製紙株式会社 可逆性感熱記録材料
WO2008104994A2 (en) 2007-02-28 2008-09-04 Advinus Therapeutics Private Limited 2,2,2-tri-substituted acetamide derivatives as glucokinase activators, their process and pharmaceutical application
AU2008329515B2 (en) 2007-11-29 2013-09-05 Merck Canada Inc. Cysteine protease inhibitors for the treatment of parasitic diseases
AR070127A1 (es) 2008-01-11 2010-03-17 Novartis Ag Pirrolo - pirimidinas y pirrolo -piridinas
CA2716514A1 (en) 2008-02-21 2009-08-27 Sequoia Pharmaceuticals, Inc. Hiv protease inhibitor and cytochrome p450 inhibitor combinations
DE102008017215B4 (de) 2008-04-04 2012-08-09 Clariant International Ltd. Kontinuierliches Verfahren zur Herstellung von Amiden ethylenisch ungesättigter Carbonsäuren
US20100055169A1 (en) 2008-04-16 2010-03-04 Abbott Laboratories Cationic lipids and uses thereof
AR072518A1 (es) 2008-07-18 2010-09-01 Sanofi Aventis Derivados de imidazo [1,2-a]piridina, su procedimiento de preparacion, composiciones farmaceuticas y su utilizacion particularmente como inhibidores de met."
JP5649779B2 (ja) 2008-11-28 2015-01-07 住友化学株式会社 液晶性組成物及び光学フィルム
US8563735B2 (en) 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
DK2433940T3 (en) 2009-04-28 2015-01-12 Chugai Pharmaceutical Co Ltd Spiroimidazolonderivat
AU2010245933B2 (en) 2009-05-05 2016-06-16 Arbutus Biopharma Corporation Methods of delivering oligonucleotides to immune cells
WO2010148422A1 (en) 2009-06-25 2010-12-29 Walter And Eliza Hall Institute Of Medical Research Compounds and methods for treating parasitic infestations
US20120124896A1 (en) 2009-06-26 2012-05-24 Research Institute Of Petroleum Processing, Sinopec Diesel Composition and Method of Increasing Biodiesel Oxidation Stability
ES2360783B1 (es) 2009-10-02 2012-07-04 Consejo Superior De Investigaciones Científicas (Csic) 1,2,4-tiadiazoles-5-imino sustituidos utiles en el tratamiento de enfermedades neurodegenerativas
WO2012016188A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
WO2012020215A1 (en) 2010-08-09 2012-02-16 Centro Nacional De Investigaciones Oncológicas (Cnio) Amino- imidazolothiadiazoles for use as protein or lipid kinase inhibitors
JP2012077108A (ja) 2010-09-30 2012-04-19 Sumitomo Chemical Co Ltd ジハロビフェニル化合物及び該化合物の重合体
SG182932A1 (en) 2011-01-24 2012-08-30 Sumitomo Chemical Co Process for producing conjugated diene-based polymer, conjugated diene-based polymer, and conjugated diene-based polymer composition
BR112013027119A8 (pt) 2011-04-21 2018-03-06 Seattle Genetics Inc novos conjugados ligante-droga (adcs) e uso dos mesmos
JP6147730B2 (ja) 2011-04-27 2017-06-14 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 細胞を溶解する方法
WO2012178124A1 (en) 2011-06-22 2012-12-27 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
EP2723745A1 (en) 2011-06-22 2014-04-30 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
JP2014517079A (ja) 2011-06-22 2014-07-17 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用な化合物
WO2013005057A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncológicas (Cnio) New compounds
DE102011079846B4 (de) 2011-07-26 2014-02-06 Merck Patent Gmbh Komplexverbindungen mit einem mehrzähnigen, asymmetrischen Liganden und ihre Verwendung im opto-elektronischen Bereich
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
IN2014CN03043A (lt) 2011-09-30 2015-07-03 Univ Tufts
BR112014009306B1 (pt) * 2011-10-20 2021-07-20 Oryzon Genomics S.A. Compostos de (hetero)aril ciclopropilamina como inibidores de lsd1
WO2013068075A1 (de) 2011-11-11 2013-05-16 Merck Patent Gmbh Verfahren zur herstellung von arylaminen
MX352923B (es) 2012-05-09 2017-12-14 Sasol Tech Pty Ltd Oligomerizacion de compuestos olefinicos con menor formacion de polimeros.
EP2887804B1 (en) 2012-05-22 2021-01-27 Trustees of Dartmouth College Cycloalkanyl[b]indoles useful as glp-1 modulators
SG11201501620QA (en) 2012-09-18 2015-04-29 Heptares Therapeutics Ltd Bicyclic aza compounds as muscarinic m1 receptor agonists
EP2900680A4 (en) 2012-09-28 2016-06-08 Univ Tufts URIDEINDIPHOSPHATE DERIVATIVES, PRODRUGS, COMPOSITIONS AND USES THEREOF
DE102012109685A1 (de) 2012-10-11 2014-04-17 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verfahren zur Umwandlung reaktiver Gruppen an Si-C-gebundenen Resten von Silanen unter gleichzeitiger Vergrößerung von deren räumlichem Abstand zueinander
JP6387829B2 (ja) 2012-10-26 2018-09-12 コニカミノルタ株式会社 光学フィルム、円偏光板及び画像表示装置
KR101677866B1 (ko) 2012-10-29 2016-11-18 코니카 미놀타 가부시키가이샤 위상차 필름, 원편광판 및 화상 표시 장치
JP5902641B2 (ja) 2013-03-27 2016-04-13 富士フイルム株式会社 光干渉顔料およびその製造方法
JP2014232188A (ja) 2013-05-29 2014-12-11 コニカミノルタ株式会社 セルロースアシレートフィルム、円偏光板及び画像表示装置
WO2014210564A1 (en) 2013-06-27 2014-12-31 Academia Sinica Glycan conjugates and use thereof
JP2015030699A (ja) 2013-08-02 2015-02-16 マナック株式会社 アルカリ金属ハロゲン化物を用いたベンジルアミン類及びベンジルエーテル類の酸化的脱ベンジル化反応
FR3009309B1 (fr) 2013-08-02 2016-10-07 Total Marketing Services Compositions lubrifiantes pour transmissions
JP2016536170A (ja) 2013-08-19 2016-11-24 クィーンズ ユニバーシティー アット キングストン カルベンにより官能化された複合材料
KR102181235B1 (ko) 2013-08-30 2020-11-23 삼성디스플레이 주식회사 축합환 화합물 및 이를 포함한 유기 발광 소자
KR102167042B1 (ko) 2013-09-06 2020-10-19 삼성디스플레이 주식회사 축합환 화합물 및 이를 포함한 유기 발광 소자
KR102191991B1 (ko) 2013-09-06 2020-12-17 삼성디스플레이 주식회사 축합환 화합물 및 이를 포함한 유기 발광 소자
KR102191990B1 (ko) 2013-09-10 2020-12-17 삼성디스플레이 주식회사 축합환 화합물 및 이를 포함한 유기 발광 소자
KR20150091942A (ko) 2014-02-04 2015-08-12 삼성전자주식회사 유기금속 화합물 및 이를 포함한 유기 발광 소자
WO2015126357A1 (en) 2014-02-18 2015-08-27 Renmatix, Inc. Method of reducing a fermentation and/or enzyme inhibitor in a saccharide-containing composition
US20150239918A1 (en) 2014-02-27 2015-08-27 Robert Lee Johnson Functionalized carbon matrix materials
WO2015133247A1 (ja) 2014-03-07 2015-09-11 独立行政法人産業技術総合研究所 カルバミン酸エステルの製造方法
TWI687419B (zh) * 2014-07-10 2020-03-11 美商英塞特公司 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪
CN107438593B (zh) 2015-01-30 2020-10-30 基因泰克公司 治疗化合物及其用途
WO2016172496A1 (en) 2015-04-23 2016-10-27 Constellation Pharmaceuticals, Inc. Lsd1 inhibitors and uses thereof
HRP20231369T1 (hr) * 2016-10-26 2024-02-16 Constellation Pharmaceuticals, Inc. Inhibitori lsd1 i njihova medicinska upotreba
US20200069677A1 (en) * 2016-12-09 2020-03-05 Constellation Pharmaceuticals, Inc. Markers for personalized cancer treatment with lsd1 inhibitors

Also Published As

Publication number Publication date
HRP20231369T1 (hr) 2024-02-16
JP2019537584A (ja) 2019-12-26
RS64889B1 (sr) 2023-12-29
TWI753037B (zh) 2022-01-21
US20200306223A1 (en) 2020-10-01
HUE063848T2 (hu) 2024-02-28
CN109863137B (zh) 2022-12-16
US20190274998A1 (en) 2019-09-12
ES2961499T3 (es) 2024-03-12
AU2017348100A1 (en) 2019-05-02
AU2017348100B2 (en) 2021-08-26
PT3532459T (pt) 2023-11-10
SI3532459T1 (sl) 2024-03-29
US20220079917A1 (en) 2022-03-17
CN109863137A (zh) 2019-06-07
TW201821406A (zh) 2018-06-16
FI3532459T3 (fi) 2023-10-23
US10517849B2 (en) 2019-12-31
US11547695B2 (en) 2023-01-10
DK3532459T3 (da) 2023-10-30
EP3532459B1 (en) 2023-08-02
WO2018081343A1 (en) 2018-05-03
CA3039793A1 (en) 2018-05-03
EP3532459A1 (en) 2019-09-04
JP7142633B2 (ja) 2022-09-27
US11013718B2 (en) 2021-05-25

Similar Documents

Publication Publication Date Title
IL265922A (en) tyk2 inhibitors and uses thereof
IL266109A (en) tyk2 inhibitors and uses thereof
IL271999A (en) TYK2 inhibitors and uses thereof
HK1248690A1 (zh) 酪胺酸蛋白質激酶2(tyk2)抑制劑及其用途
HK1256997A1 (zh) Tyk2抑制劑及其用途
HK1243072A1 (zh) 布羅莫結構域抑制劑及其用途
EP3389658A4 (en) GLYCOSIDASE INHIBITORS AND USES THEREOF
HUE063848T2 (hu) LSD1 gátlók és gyógyászati alkalmazásaik
EP3110820A4 (en) Tyk2 inhibitors and uses thereof
GB201605126D0 (en) Inhibitors and their uses
IL262387A (en) Arginase inhibitors and their treatment applications
PT3543240T (pt) Inibidor de urat1 e utilização deste
HUE063120T2 (hu) LRRC33-inhibitorok és alkalmazásuk
PL3240777T3 (pl) Inhibitory arginazy oraz ich zastosowania terapeutyczne
IL255530A (en) Efflux-pump inhibitors and therapeutic uses thereof
IL267238A (en) The paranase inhibitors and their use
HK1250926A1 (zh) 抑制劑及其應用
HK1255029A1 (zh) 明膠酶抑制劑及其用途
IL267243A (en) The paranase inhibitors and their use
IL247872A0 (en) stat5 inhibitors and their uses
GB2545167B (en) Cloches and use thereof
GB201505971D0 (en) Inhibitors and their uses
GB201505975D0 (en) Inhibitors and their uses